Skip to main content
SpringerLink
Log in

Palliative Chemotherapy in Advanced or Metastatic Gastric Cancer. IX-1. Overview and Cytotoxic Agents

  • Chapter
  • First Online:
Gastrointestinal Cancer

  • 394 Accesses

Abstract

Gastric cancer is one of the most common malignancies worldwide. Gastric cancer is often diagnosed at an advanced stage, except in Korea and Japan, and the prognosis of advanced gastric cancer is very poor. Due to national cancer screening programs, advanced gastric cancer is on the decline, especially in East Asia, but remains the leading cause of death elsewhere. For inoperable, advanced, or metastatic gastric cancer, palliative chemotherapy is the last treatment option. Compared to the best supportive care, palliative chemotherapy can significantly improve patient’s quality of life and survival [1]. This chapter will review the chemotherapy regimens currently available in these clinical settings.

Sun Hyung Kang is the lead author of this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.

    Article  CAS  PubMed  Google Scholar 

  2. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. ESMO guidelines committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–49.

    Article  CAS  PubMed  Google Scholar 

  3. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.

    Google Scholar 

  4. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracilalone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan clinical oncology group study (JCOG9205). J Clin Oncol. 2003;21:54–9.

    Article  CAS  PubMed  Google Scholar 

  5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.

    Article  PubMed  Google Scholar 

  6. Okines AFC, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529–34.

    Article  CAS  PubMed  Google Scholar 

  7. Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22:2403–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547–53.

    Article  CAS  PubMed  Google Scholar 

  9. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–42.

    Article  CAS  PubMed  Google Scholar 

  10. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel S, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–7.

    Article  CAS  PubMed  Google Scholar 

  11. Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010;21:71–7.

    Article  CAS  PubMed  Google Scholar 

  12. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Genuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2019;12:815–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bang YJ, Van Custem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  15. Satoh T, Bang YJ, Gotovkin EA, Hamamoto Y, Kang YK, Moiseyenko VM, et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014;19:712–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kim C, Chon HJ, Kim JH, Jung MK, Nam CM, Kim HS, et al. Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. Eur J Cancer. 2019;112:20–8.

    Article  CAS  PubMed  Google Scholar 

  17. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.

    Article  PubMed  Google Scholar 

  18. Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamakuchi K, et al. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2019;83:161–7.

    Article  CAS  PubMed  Google Scholar 

  19. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.

    Article  CAS  PubMed  Google Scholar 

  20. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.

    Article  CAS  PubMed  Google Scholar 

  21. Cunningham D, Allum WH, Stenning SP, Thompsom JN, De Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea (Republic of)

    Hoon Jai Chun

  2. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea (Republic of)

    Seun Ja Park

  3. Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Kyonggi-do, Korea (Republic of)

    Yun Jeong Lim

  4. Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, Korea (Republic of)

    Si Young Song

Authors
  1. Hoon Jai Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seun Ja Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Jeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Si Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chun, H.J., Park, S.J., Lim, Y.J., Song, S.Y. (2023). Palliative Chemotherapy in Advanced or Metastatic Gastric Cancer. IX-1. Overview and Cytotoxic Agents. In: Gastrointestinal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-99-0815-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-0815-8_9

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-0814-1

  • Online ISBN: 978-981-99-0815-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation